Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker

Trial Profile

Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Girentuximab (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Heidelberg Pharma AG
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 13 Jun 2013 Study title is not official; assumed registrational.
    • 13 Jun 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top